Pub Date : 2024-12-23DOI: 10.3390/pharmacy12060188
Kimberly C McKeirnan, Megan E Giruzzi, Damianne C Brand, Nick R Giruzzi, Kavya Vaitla, Juliet Dang
Background: Recommendations from a trusted healthcare provider have been shown to be the most effective intervention for encouraging patients to be vaccinated. However, providers have reported feeling less prepared to address vaccination questions and having less time to discuss vaccines with patients than before the COVID-19 pandemic. Providers may benefit from a brief update about the available influenza vaccines and vaccination guidelines. Academic detailing is an evidence-based approach for preparing healthcare providers to discuss getting vaccinated with patients.
Methods: An academic detailing presentation was developed using influenza statistics, vaccination recommendations, and recent local and national immunization rate data. Academic detailing was conducted with physicians and community pharmacy personnel in Yakima County, Washington, between November 2023 and January 2024. Yakima County is designated as a medically underserved area due to a lack of providers. A pre-detailing survey was conducted to evaluate participant knowledge of current ACIP recommendations and gather opinions about local resident vaccination barriers. A post-detailing survey was conducted to gather participants' opinions about the value of detailing.
Results: Prior to the training, 73% of providers believed it was important to discuss influenza vaccination with patients, but only 52% felt confident in combating misinformation. Healthcare providers believed misinformation and vaccine hesitancy are the most common barriers for Yakima County patients, but recent survey results showed that online scheduling systems, long wait times, and limited appointment hours were the predominant issues reported locally. Two out of 12 community pharmacy personnel and zero resident physicians correctly named all three preferentially recommended influenza vaccines for patients 65 years and older. Overall, 96% of detailing participants reported that the session was valuable, 87% believed it would help them combat vaccine misinformation, and 65% reported planning to have more conversations with patients about influenza vaccination after participating.
Conclusion: Physicians and community pharmacy immunizers found the influenza vaccines academic detailing to be valuable. Staying up to date on vaccination guidelines can prepare providers to be confident in having informed conversations with patients about getting vaccinated.
{"title":"Education for Healthcare Providers: Impact of Academic Detailing on Reducing Misinformation and Strengthening Influenza Vaccine Recommendations.","authors":"Kimberly C McKeirnan, Megan E Giruzzi, Damianne C Brand, Nick R Giruzzi, Kavya Vaitla, Juliet Dang","doi":"10.3390/pharmacy12060188","DOIUrl":"10.3390/pharmacy12060188","url":null,"abstract":"<p><strong>Background: </strong>Recommendations from a trusted healthcare provider have been shown to be the most effective intervention for encouraging patients to be vaccinated. However, providers have reported feeling less prepared to address vaccination questions and having less time to discuss vaccines with patients than before the COVID-19 pandemic. Providers may benefit from a brief update about the available influenza vaccines and vaccination guidelines. Academic detailing is an evidence-based approach for preparing healthcare providers to discuss getting vaccinated with patients.</p><p><strong>Methods: </strong>An academic detailing presentation was developed using influenza statistics, vaccination recommendations, and recent local and national immunization rate data. Academic detailing was conducted with physicians and community pharmacy personnel in Yakima County, Washington, between November 2023 and January 2024. Yakima County is designated as a medically underserved area due to a lack of providers. A pre-detailing survey was conducted to evaluate participant knowledge of current ACIP recommendations and gather opinions about local resident vaccination barriers. A post-detailing survey was conducted to gather participants' opinions about the value of detailing.</p><p><strong>Results: </strong>Prior to the training, 73% of providers believed it was important to discuss influenza vaccination with patients, but only 52% felt confident in combating misinformation. Healthcare providers believed misinformation and vaccine hesitancy are the most common barriers for Yakima County patients, but recent survey results showed that online scheduling systems, long wait times, and limited appointment hours were the predominant issues reported locally. Two out of 12 community pharmacy personnel and zero resident physicians correctly named all three preferentially recommended influenza vaccines for patients 65 years and older. Overall, 96% of detailing participants reported that the session was valuable, 87% believed it would help them combat vaccine misinformation, and 65% reported planning to have more conversations with patients about influenza vaccination after participating.</p><p><strong>Conclusion: </strong>Physicians and community pharmacy immunizers found the influenza vaccines academic detailing to be valuable. Staying up to date on vaccination guidelines can prepare providers to be confident in having informed conversations with patients about getting vaccinated.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-15DOI: 10.3390/pharmacy12060187
Raffaele La Regina, Pasquale Innelli, Fulvio Glisenti, Gianbattista Bollani, Eugenio Leopardi, Gian Franco Gensini, Savina Nodari, Giuseppe La Regina, Micaela La Regina, Francesco Gabbrielli
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias of clinical relevance and a major cause of cardiovascular morbidity and mortality. Following a diagnosis of AF, patients are directed towards therapy with anticoagulant drugs to reduce the thromboembolic risk and antiarrhythmics to control their cardiac rhythm, with periodic follow-up checks. Despite the great ease of handling these drugs, we soon realized the need for follow-up models that would allow the appropriateness and safety of these pharmacological treatments to be monitored over time. This pilot study was conducted at a rural pharmacy. The study comprised 47 patients (average age 71.22 years) with nonvalvular atrial fibrillation (68% being paroxysmal) on NOACs. Twenty percent of the enrolled subjects lived alone and fifty-four percent of the participants stated that they were not independent in managing their treatment. The primary aim was to describe the implementation and the outcomes of an innovative smart clinic model in which a local trained pharmacist is a case manager, and the patient carries out the required checks via telemedicine and point-of-care testing systems (POCT) under the service pharmacy regime; the results of the checks could be shared in real time with the attending general practitioner and the relevant specialist. The secondary aims of this study were to evaluate adherence to the planned controls, the prescriptive appropriateness of the dosages and drugs and adherence to the prescribed therapy, the occurrence of pharmacological problems linked to drug type interactions, the occurrence of hemorrhagic and/or thromboembolic complications, the acceptance by the general practitioners and/or the specialists of the reports made by the pharmacist on the subsequent actions undertaken, the economic and social impact of this model on the National Health Service and on the patient, and the impact on the quality perceived by the patients involved in this innovative monitoring process. Compliance with the planned checks was 93%. The dosage of the anticoagulant drug during enrollment was found to be inappropriate, without apparent clinical reasons, in 11% of the sample. Adherence to the anticoagulant therapy was found to be 98%. In total, 214 drug-drug interactions of varying clinical relevance were detected. No embolic events were detected; however, 13% of the sample reported a major hemorrhagic event, which came to light thanks to the close monitoring of hemoglobinemia. A total of 109 reports were made to the patients' referring doctors in relation to the summarized anomalies, and 84% were accepted by the referring clinicians. Therefore, community pharmacists and pharmacy services represent ideal actors and contexts that, when integrated into the care network, can really favor individual care plan adherence and achieve daily morbidity reductions and cost savings through proper disease control and the early diagnosis of complications.
{"title":"AIHEMAF-P: An Innovative Healthcare Model for Atrial Fibrillation Patients.","authors":"Raffaele La Regina, Pasquale Innelli, Fulvio Glisenti, Gianbattista Bollani, Eugenio Leopardi, Gian Franco Gensini, Savina Nodari, Giuseppe La Regina, Micaela La Regina, Francesco Gabbrielli","doi":"10.3390/pharmacy12060187","DOIUrl":"10.3390/pharmacy12060187","url":null,"abstract":"<p><p>Atrial fibrillation (AF) is one of the most common cardiac arrhythmias of clinical relevance and a major cause of cardiovascular morbidity and mortality. Following a diagnosis of AF, patients are directed towards therapy with anticoagulant drugs to reduce the thromboembolic risk and antiarrhythmics to control their cardiac rhythm, with periodic follow-up checks. Despite the great ease of handling these drugs, we soon realized the need for follow-up models that would allow the appropriateness and safety of these pharmacological treatments to be monitored over time. This pilot study was conducted at a rural pharmacy. The study comprised 47 patients (average age 71.22 years) with nonvalvular atrial fibrillation (68% being paroxysmal) on NOACs. Twenty percent of the enrolled subjects lived alone and fifty-four percent of the participants stated that they were not independent in managing their treatment. The primary aim was to describe the implementation and the outcomes of an innovative smart clinic model in which a local trained pharmacist is a case manager, and the patient carries out the required checks via telemedicine and point-of-care testing systems (POCT) under the service pharmacy regime; the results of the checks could be shared in real time with the attending general practitioner and the relevant specialist. The secondary aims of this study were to evaluate adherence to the planned controls, the prescriptive appropriateness of the dosages and drugs and adherence to the prescribed therapy, the occurrence of pharmacological problems linked to drug type interactions, the occurrence of hemorrhagic and/or thromboembolic complications, the acceptance by the general practitioners and/or the specialists of the reports made by the pharmacist on the subsequent actions undertaken, the economic and social impact of this model on the National Health Service and on the patient, and the impact on the quality perceived by the patients involved in this innovative monitoring process. Compliance with the planned checks was 93%. The dosage of the anticoagulant drug during enrollment was found to be inappropriate, without apparent clinical reasons, in 11% of the sample. Adherence to the anticoagulant therapy was found to be 98%. In total, 214 drug-drug interactions of varying clinical relevance were detected. No embolic events were detected; however, 13% of the sample reported a major hemorrhagic event, which came to light thanks to the close monitoring of hemoglobinemia. A total of 109 reports were made to the patients' referring doctors in relation to the summarized anomalies, and 84% were accepted by the referring clinicians. Therefore, community pharmacists and pharmacy services represent ideal actors and contexts that, when integrated into the care network, can really favor individual care plan adherence and achieve daily morbidity reductions and cost savings through proper disease control and the early diagnosis of complications.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-10DOI: 10.3390/pharmacy12060186
Ciarra A Boyne, Tammie M Johnson, Lindsay P Toth, Michael R Richardson, James R Churilla
While previous research has linked physical activity (PA) with lower prescription medication consumption, limited evidence has investigated sedentary time (ST) as a major contributor to medication use, despite ST's known association with chronic disease and mortality risk, even when PA volume is considered. This study aimed to examine the independent associations between objectively measured ST, patterns of sedentary bouts, and self-reported prescription medication use among adults ≥25 years of age. Thirty-two participants reported the number and type of medications they were currently prescribed and wore an accelerometer continuously on their hip for seven days to detect their ST. Poisson regression analysis was used to assess how average daily ST, sedentary bout frequency, and sedentary bout duration influenced medication use. The results revealed a significant association between greater ST and higher medication consumption. Specifically, each additional hour of ST per day, each sedentary bout, and each one-minute increase in bout duration were linked to a 66% (PR 1.66; 95% CI 1.25-2.19; p < 0.001), 36% (PR 1.36; 95% CI 1.12-1.64; p < 0.01), and 9% (PR 1.09; 95% CI 1.03-1.16; p < 0.01) higher prevalence of prescription medications, respectively. These findings suggest that higher ST is associated with a greater prevalence of using prescription medications in adults.
尽管以往的研究将体力活动(PA)与较低的处方药用量联系在一起,但对久坐时间(ST)作为用药主要因素的调查证据却很有限,尽管久坐时间与慢性疾病和死亡风险有关,即使考虑到体力活动量也是如此。本研究旨在考察年龄≥25 岁的成年人客观测量的久坐时间、久坐模式和自我报告的处方药使用量之间的独立关联。32 名参与者报告了他们目前处方药的数量和类型,并连续 7 天在臀部佩戴加速度计以检测他们的 ST。研究人员使用泊松回归分析法评估了日均ST、久坐频率和久坐时间对药物使用的影响。结果显示,静坐时间越长,用药量越大,两者之间存在明显的关联。具体来说,每天ST时间每增加一小时、每次久坐和每次久坐时间每增加一分钟,处方药的使用率就分别增加66% (PR 1.66; 95% CI 1.25-2.19; p < 0.001)、36% (PR 1.36; 95% CI 1.12-1.64; p < 0.01) 和 9% (PR 1.09; 95% CI 1.03-1.16; p < 0.01)。这些结果表明,ST 越高,成人使用处方药的比例越高。
{"title":"Objectively-Measured Sedentary Time and Self-Reported Prescription Medication Use Among Adults: A Pilot Study.","authors":"Ciarra A Boyne, Tammie M Johnson, Lindsay P Toth, Michael R Richardson, James R Churilla","doi":"10.3390/pharmacy12060186","DOIUrl":"10.3390/pharmacy12060186","url":null,"abstract":"<p><p>While previous research has linked physical activity (PA) with lower prescription medication consumption, limited evidence has investigated sedentary time (ST) as a major contributor to medication use, despite ST's known association with chronic disease and mortality risk, even when PA volume is considered. This study aimed to examine the independent associations between objectively measured ST, patterns of sedentary bouts, and self-reported prescription medication use among adults ≥25 years of age. Thirty-two participants reported the number and type of medications they were currently prescribed and wore an accelerometer continuously on their hip for seven days to detect their ST. Poisson regression analysis was used to assess how average daily ST, sedentary bout frequency, and sedentary bout duration influenced medication use. The results revealed a significant association between greater ST and higher medication consumption. Specifically, each additional hour of ST per day, each sedentary bout, and each one-minute increase in bout duration were linked to a 66% (PR 1.66; 95% CI 1.25-2.19; <i>p</i> < 0.001), 36% (PR 1.36; 95% CI 1.12-1.64; <i>p</i> < 0.01), and 9% (PR 1.09; 95% CI 1.03-1.16; <i>p</i> < 0.01) higher prevalence of prescription medications, respectively. These findings suggest that higher ST is associated with a greater prevalence of using prescription medications in adults.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-05DOI: 10.3390/pharmacy12060185
Abbie L Blunier, R Jake Crocker, Rachel Foster, Stephanie S May, Caroline E Powers, P Brandon Bookstaver
Cephalosporins have traditionally been administered as an intermittent infusion. With the knowledge that cephalosporins demonstrate a time-dependent pharmacodynamic profile, administration via continuous infusion may provide more effective antibiotic exposure for successful therapy. Proposed benefits of administration via continuous infusion include less IV manipulation, decreased potential for antibiotic resistance, and potential cost savings. The objective of this review was to provide a detailed assessment of available evidence for the use of continuous infusion cephalosporins and practical dosing and administration recommendations. Studies were gathered and assessed for inclusion via a literature search of PubMed and Ovid MEDLINE using mesh terms ["continuous infusion" and "cephalosporin"], "intermittent infusion", ["intermittent versus continuous" and "cephalosporin"], "continuous infusion cephalosporin", as well as specific drug names. References from included studies were also evaluated for inclusion. Data which compared the two administration methods (continuous infusion vs. intermittent infusion) were evaluated. Thirty-five studies were analyzed among several cephalosporins with variable delivery. Dosing regimens utilized in the selected studies were assessed with known compatibility and stability data and further summarized.
{"title":"Rationale and Logistics of Continuous Infusion Cephalosporin Antibiotics.","authors":"Abbie L Blunier, R Jake Crocker, Rachel Foster, Stephanie S May, Caroline E Powers, P Brandon Bookstaver","doi":"10.3390/pharmacy12060185","DOIUrl":"10.3390/pharmacy12060185","url":null,"abstract":"<p><p>Cephalosporins have traditionally been administered as an intermittent infusion. With the knowledge that cephalosporins demonstrate a time-dependent pharmacodynamic profile, administration via continuous infusion may provide more effective antibiotic exposure for successful therapy. Proposed benefits of administration via continuous infusion include less IV manipulation, decreased potential for antibiotic resistance, and potential cost savings. The objective of this review was to provide a detailed assessment of available evidence for the use of continuous infusion cephalosporins and practical dosing and administration recommendations. Studies were gathered and assessed for inclusion via a literature search of PubMed and Ovid MEDLINE using mesh terms [\"continuous infusion\" and \"cephalosporin\"], \"intermittent infusion\", [\"intermittent versus continuous\" and \"cephalosporin\"], \"continuous infusion cephalosporin\", as well as specific drug names. References from included studies were also evaluated for inclusion. Data which compared the two administration methods (continuous infusion vs. intermittent infusion) were evaluated. Thirty-five studies were analyzed among several cephalosporins with variable delivery. Dosing regimens utilized in the selected studies were assessed with known compatibility and stability data and further summarized.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-05DOI: 10.3390/pharmacy12060184
Rie Sato, Syuichi Aoshima, Tommy Eriksson
(1) Background: In general, it is known that continuity of care can contribute to an increase in patient satisfaction, reduce health care costs, and improve patient outcomes. A guarantee of continuity in pharmacotherapy is a big challenge facing Japanese health care as a system that encourages cooperation/collaboration for pharmacists with other health care professions is currently lacking. (2) Method: This is a narrative review. (3) Results: The Lund Integrated Medicine Management (LIMM) model describes a systematic approach to individuals and was developed in Sweden to optimize pharmacotherapy among elderly inpatients. The aim of the LIMM model is to provide patients with continuous pharmacotherapy at different levels of care. The LIMM model, in which a clinical pharmacist is the catalyst and leads other health care professions in completing the process, has the potential to reduce potentially inappropriate prescriptions, reduce rehospitalization risk, unscheduled hospital revisits due to problems related to medications, reduce total medical expenditure, and provide a comprehensive understanding of patients' conditions of taking medicine. (4) Conclusions: Introducing a framework such as Sweden's LIMM model, anchored by clinical pharmacists, could provide a good opportunity to promote collaborations among different health care professionals and improve continuity in pharmacotherapy.
(1)背景:一般来说,连续性护理有助于提高患者满意度,降低医疗保健成本,改善患者预后。保证药物治疗的连续性是日本卫生保健面临的一个巨大挑战,因为目前缺乏鼓励药剂师与其他卫生保健专业人员合作的系统。(2)方法:这是一个叙述性的回顾。(3)结果:隆德综合医学管理(Lund Integrated Medicine Management, LIMM)模型描述了一种针对个体的系统方法,该模型由瑞典开发,用于优化老年住院患者的药物治疗。LIMM模型的目的是在不同的护理水平上为患者提供持续的药物治疗。在LIMM模式中,临床药剂师是催化剂,并领导其他医疗保健专业人员完成这一过程,这一模式有可能减少潜在的不适当处方,降低再住院风险,减少因药物相关问题而非计划的医院复诊,减少医疗总支出,并提供对患者服药情况的全面了解。(4)结论:以临床药师为主体,引入瑞典的LIMM模式等框架,可以促进不同医疗专业人员之间的合作,提高药物治疗的连续性。
{"title":"Clinical Pharmacist-Led Collaboration of Multiple Clinical Professions Model Focusing on Continuity of Pharmacotherapy: Japanese Version of the Lund Integrated Medicines Management (LIMM) Model.","authors":"Rie Sato, Syuichi Aoshima, Tommy Eriksson","doi":"10.3390/pharmacy12060184","DOIUrl":"10.3390/pharmacy12060184","url":null,"abstract":"<p><p>(1) Background: In general, it is known that continuity of care can contribute to an increase in patient satisfaction, reduce health care costs, and improve patient outcomes. A guarantee of continuity in pharmacotherapy is a big challenge facing Japanese health care as a system that encourages cooperation/collaboration for pharmacists with other health care professions is currently lacking. (2) Method: This is a narrative review. (3) Results: The Lund Integrated Medicine Management (LIMM) model describes a systematic approach to individuals and was developed in Sweden to optimize pharmacotherapy among elderly inpatients. The aim of the LIMM model is to provide patients with continuous pharmacotherapy at different levels of care. The LIMM model, in which a clinical pharmacist is the catalyst and leads other health care professions in completing the process, has the potential to reduce potentially inappropriate prescriptions, reduce rehospitalization risk, unscheduled hospital revisits due to problems related to medications, reduce total medical expenditure, and provide a comprehensive understanding of patients' conditions of taking medicine. (4) Conclusions: Introducing a framework such as Sweden's LIMM model, anchored by clinical pharmacists, could provide a good opportunity to promote collaborations among different health care professionals and improve continuity in pharmacotherapy.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11679876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-04DOI: 10.3390/pharmacy12060182
Milana Špoģe, Mirdza Kursīte, Elita Poplavska
Background: Valproates are recognized for their significant teratogenic risks, which can lead to physical defects and developmental disorders when used during pregnancy. To mitigate these risks, the Pregnancy Prevention Program (PPP) was developed by European regulators for patients and healthcare professionals (HCPs). Despite the crucial nature of this program, the implementation of the PPP does not appear to be fully effective. This situation highlights the need for a deeper understanding of HCPs' knowledge, attitudes, and behaviors regarding the PPP.
Methods: A cross-sectional study using anonymous electronic questionnaires was conducted. The questionnaires were developed by a board of experts from eight different EU countries and were distributed among prescribers (general practitioners (GPs), neurologists, and psychiatrists) and pharmacists. Descriptive statistics were used to analyze the obtained data on participants' knowledge, attitudes, and behaviors regarding the prescribing and dispensing of valproate-containing medicines to women of reproductive age, as well as the impact of PPP materials on their work.
Results: The study results indicate that while HCPs in Latvia are generally aware of valproate teratogenic risks, significant gaps remain in the implementation of the PPP. A considerable number of both prescribers and pharmacists expressed the belief that they are not responsible for educating patients about the PPP, attributing this responsibility to other specialists. Furthermore, barriers such as a lack of time and accessible materials were identified.
Conclusions: The roles and responsibilities of HCPs should be clearly defined to improve adherence to the PPP. Further research is needed to assess prescription and dispensing strategies, as well as HCPs' attitudes toward the PPP. Additionally, re-evaluating and enhancing the accessibility of PPP materials is essential in effective risk management and better patient care.
{"title":"Latvian Healthcare Professionals' Self-Reported Knowledge, Attitudes, and Behaviors Related to Pregnancy Prevention Program Materials for Valproate-Containing Medicines.","authors":"Milana Špoģe, Mirdza Kursīte, Elita Poplavska","doi":"10.3390/pharmacy12060182","DOIUrl":"10.3390/pharmacy12060182","url":null,"abstract":"<p><strong>Background: </strong>Valproates are recognized for their significant teratogenic risks, which can lead to physical defects and developmental disorders when used during pregnancy. To mitigate these risks, the Pregnancy Prevention Program (PPP) was developed by European regulators for patients and healthcare professionals (HCPs). Despite the crucial nature of this program, the implementation of the PPP does not appear to be fully effective. This situation highlights the need for a deeper understanding of HCPs' knowledge, attitudes, and behaviors regarding the PPP.</p><p><strong>Methods: </strong>A cross-sectional study using anonymous electronic questionnaires was conducted. The questionnaires were developed by a board of experts from eight different EU countries and were distributed among prescribers (general practitioners (GPs), neurologists, and psychiatrists) and pharmacists. Descriptive statistics were used to analyze the obtained data on participants' knowledge, attitudes, and behaviors regarding the prescribing and dispensing of valproate-containing medicines to women of reproductive age, as well as the impact of PPP materials on their work.</p><p><strong>Results: </strong>The study results indicate that while HCPs in Latvia are generally aware of valproate teratogenic risks, significant gaps remain in the implementation of the PPP. A considerable number of both prescribers and pharmacists expressed the belief that they are not responsible for educating patients about the PPP, attributing this responsibility to other specialists. Furthermore, barriers such as a lack of time and accessible materials were identified.</p><p><strong>Conclusions: </strong>The roles and responsibilities of HCPs should be clearly defined to improve adherence to the PPP. Further research is needed to assess prescription and dispensing strategies, as well as HCPs' attitudes toward the PPP. Additionally, re-evaluating and enhancing the accessibility of PPP materials is essential in effective risk management and better patient care.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11679773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-04DOI: 10.3390/pharmacy12060183
Samantha S Bastow, Eric P Borrelli, Julia D Lucaci, Heather Nelkin, April Graves, Amanda Hays
This study explored controlled substance (CS) diversion surveillance practices within hospital pharmacies across the United States. A survey with questions based on published CS diversion risk points was conducted in May 2024. A total of 66 participants from 31 states responded, with 54.5% from single facilities and the remaining from health systems. Most respondents were pharmacy directors, managers, or those in dedicated drug diversion roles. Over 70% have dedicated surveillance teams and use drug diversion software. Results highlight variation in practices, with larger institutions generally showing better compliance. Compliance in procurement and receiving was high for access measures; however, auditing of processes was lower. The lowest procurement compliance was in monitoring periodic automatic replacement (PAR) levels and validating orders with wholesalers. Storage practices showed high compliance in deploying cameras, but low compliance in monitoring them. Dispensing practices had high compliance for restricting CS in automated dispensing cabinets, but low incidence of witness verification during stocking. Waste and disposal practices were well-followed, but training on detecting potential signs of medication tampering was less common. The survey highlights that while strategies to prevent CS diversion exist, their implementation varies. Enhancing monitoring, auditing, and training is essential to strengthen diversion prevention efforts in hospital pharmacies.
{"title":"Insights from a National Survey on Controlled Substance Diversion Practices in U.S. Hospital Pharmacies: Opportunities for Enhanced Surveillance and Compliance.","authors":"Samantha S Bastow, Eric P Borrelli, Julia D Lucaci, Heather Nelkin, April Graves, Amanda Hays","doi":"10.3390/pharmacy12060183","DOIUrl":"10.3390/pharmacy12060183","url":null,"abstract":"<p><p>This study explored controlled substance (CS) diversion surveillance practices within hospital pharmacies across the United States. A survey with questions based on published CS diversion risk points was conducted in May 2024. A total of 66 participants from 31 states responded, with 54.5% from single facilities and the remaining from health systems. Most respondents were pharmacy directors, managers, or those in dedicated drug diversion roles. Over 70% have dedicated surveillance teams and use drug diversion software. Results highlight variation in practices, with larger institutions generally showing better compliance. Compliance in procurement and receiving was high for access measures; however, auditing of processes was lower. The lowest procurement compliance was in monitoring periodic automatic replacement (PAR) levels and validating orders with wholesalers. Storage practices showed high compliance in deploying cameras, but low compliance in monitoring them. Dispensing practices had high compliance for restricting CS in automated dispensing cabinets, but low incidence of witness verification during stocking. Waste and disposal practices were well-followed, but training on detecting potential signs of medication tampering was less common. The survey highlights that while strategies to prevent CS diversion exist, their implementation varies. Enhancing monitoring, auditing, and training is essential to strengthen diversion prevention efforts in hospital pharmacies.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-02DOI: 10.3390/pharmacy12060181
Zehra Hajrulai-Musliu, Elizabeta Dimitreska Stojkovikj, Dimitar Gusheski, Dea Musliu, Daniel Velkovski
The study highlights the need for quality control in evaluating medicinal plant products, especially CBD oils, before market release. Due to varying regulatory requirements, product labeling can sometimes be misleading, especially regarding cannabinoid concentrations such as CBD and THC. This research focused on developing a validated high-performance liquid chromatography (HPLC) method for accurately identifying and quantifying key cannabinoids in Commercial Veterinary CBD Oil. The main compounds identified included Cannabidivarin (CBDV), Cannabidiolic Acid (CBD-A), Cannabigerolic Acid (CBG-A), Cannabigerol (CBG), Cannabidiol (CBD), Tetrahydrocannabivarin (THCV), Cannabinol (CBN), ∆9-Tetrahydrocannabinol (d9-THC) ∆8-Tetrahydrocannabinol (d8-THC), Cannabicyclol (CBL), Cannabichromene (CBC), and Tetrahydrocannabinolic Acid (THCA), determined in line with the International Conference on Harmonization's (ICH) guidelines. The method was validated for linearity, accuracy, precision, limit of detection (LOD), and limit of quantitation (LOQ). It was determined to be linear, with a correlation coefficient (R²) > 0.999. The LOD and LOQ values calculated from the calibration curve ranged from 0.05 to 0.13 and 0.50 to 0.61 µg/mL, respectively. The method also exhibited acceptable precision, with relative standard deviation values lower than or equal to 2%. The method's accuracy was assessed through recovery percentages and fell within an acceptable range of 98-102 if the RSD was 2%. This study's rigorous methodology and comprehensive findings significantly contribute to cannabinoid analysis. This validated protocol was used to analyze cannabinoids in 14 commercial veterinary CBD oil products from the Republic of North Macedonia. The performance parameters demonstrated that the method is reliable for quantitatively measuring cannabinoids in CBD oil. The analysis showed that the cannabinoid levels in the products were consistent with the manufacturers' declared specifications, with no significant discrepancies in labeling.
{"title":"High-Performance Liquid Chromatography with DAD Detection for the Determination of Cannabinoids in Commercial Veterinary CBD Oil.","authors":"Zehra Hajrulai-Musliu, Elizabeta Dimitreska Stojkovikj, Dimitar Gusheski, Dea Musliu, Daniel Velkovski","doi":"10.3390/pharmacy12060181","DOIUrl":"10.3390/pharmacy12060181","url":null,"abstract":"<p><p>The study highlights the need for quality control in evaluating medicinal plant products, especially CBD oils, before market release. Due to varying regulatory requirements, product labeling can sometimes be misleading, especially regarding cannabinoid concentrations such as CBD and THC. This research focused on developing a validated high-performance liquid chromatography (HPLC) method for accurately identifying and quantifying key cannabinoids in Commercial Veterinary CBD Oil. The main compounds identified included Cannabidivarin (CBDV), Cannabidiolic Acid (CBD-A), Cannabigerolic Acid (CBG-A), Cannabigerol (CBG), Cannabidiol (CBD), Tetrahydrocannabivarin (THCV), Cannabinol (CBN), ∆<sup>9</sup>-Tetrahydrocannabinol (d9-THC) ∆8-Tetrahydrocannabinol (d8-THC), Cannabicyclol (CBL), Cannabichromene (CBC), and Tetrahydrocannabinolic Acid (THCA), determined in line with the International Conference on Harmonization's (ICH) guidelines. The method was validated for linearity, accuracy, precision, limit of detection (LOD), and limit of quantitation (LOQ). It was determined to be linear, with a correlation coefficient (R²) > 0.999. The LOD and LOQ values calculated from the calibration curve ranged from 0.05 to 0.13 and 0.50 to 0.61 µg/mL, respectively. The method also exhibited acceptable precision, with relative standard deviation values lower than or equal to 2%. The method's accuracy was assessed through recovery percentages and fell within an acceptable range of 98-102 if the RSD was 2%. This study's rigorous methodology and comprehensive findings significantly contribute to cannabinoid analysis. This validated protocol was used to analyze cannabinoids in 14 commercial veterinary CBD oil products from the Republic of North Macedonia. The performance parameters demonstrated that the method is reliable for quantitatively measuring cannabinoids in CBD oil. The analysis showed that the cannabinoid levels in the products were consistent with the manufacturers' declared specifications, with no significant discrepancies in labeling.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.3390/pharmacy12060180
Aleena Shahzad, Anees Ur Rehman, Tehnia Naz, Muhammad Fawad Rasool, Alisha Saeed, Saba Rasheed, Sadia Shakeel, Saleh Karamah Al-Tamimi, Rabia Hussain
Background and Objectives: Cervical cancer is the third leading cause of cancer-related mortality in females. One of the most successful therapeutic modalities to date is suppressing vascular endothelial growth factor (VEGF)-mediated angiogenesis. Bevacizumab is a monoclonal antibody that targets VEGF-A. The outcomes for cervical cancer patients treated with bevacizumab in combination with platinum-based chemotherapy have been explored in several studies. This study aimed to assess the impact of bevacizumab on progression-free survival (PFS) and overall survival (OS) in patients with metastatic cervical cancer. Materials and Methods: This systematic review was registered in PROSPERO (CRD42023456755). Following PRISMA guidelines, a comprehensive literature search on PubMed and Google Scholar identified 28 studies meeting the inclusion criteria. The outcomes of interest were PFS and OS. The statistical analysis computed hazard ratios (HRs) with 95% confidence intervals (CIs). The study also included a subgroup analysis by cervical cancer stage. Results: The pooled analysis revealed that bevacizumab-based therapy significantly improved both PFS with HR 0.77 (95% CI: 0.58-0.96; p < 0.01; I2 = 58%) and OS with HR 0.63 (95% CI: 0.45-0.89; p < 0.01; I2 = 41%) in cervical cancer patients. Subgroup analysis by stage of cervical cancer demonstrated better efficacy of bevacizumab in metastatic stage IVB cervical cancer patients indicated by HR for PFS (0.69, 95% CI: 0.54-0.79; p < 0.01) and HR for OS (0.57, 95% CI: 0.46-0.73; p < 0.01). Conclusions: Bevacizumab exhibits a significant increase in PFS and OS, underscoring the efficacy of anti-angiogenesis therapy in cervical cancer, particularly in stage IVB metastatic cervical cancer patients.
{"title":"Addition of Bevacizumab to Chemotherapy and Its Impact on Clinical Efficacy in Cervical Cancer: A Systematic Review and Meta-Analysis.","authors":"Aleena Shahzad, Anees Ur Rehman, Tehnia Naz, Muhammad Fawad Rasool, Alisha Saeed, Saba Rasheed, Sadia Shakeel, Saleh Karamah Al-Tamimi, Rabia Hussain","doi":"10.3390/pharmacy12060180","DOIUrl":"10.3390/pharmacy12060180","url":null,"abstract":"<p><p><i>Background and Objectives</i>: Cervical cancer is the third leading cause of cancer-related mortality in females. One of the most successful therapeutic modalities to date is suppressing vascular endothelial growth factor (VEGF)-mediated angiogenesis. Bevacizumab is a monoclonal antibody that targets VEGF-A. The outcomes for cervical cancer patients treated with bevacizumab in combination with platinum-based chemotherapy have been explored in several studies. This study aimed to assess the impact of bevacizumab on progression-free survival (PFS) and overall survival (OS) in patients with metastatic cervical cancer. <i>Materials and Methods</i>: This systematic review was registered in PROSPERO (CRD42023456755). Following PRISMA guidelines, a comprehensive literature search on PubMed and Google Scholar identified 28 studies meeting the inclusion criteria. The outcomes of interest were PFS and OS. The statistical analysis computed hazard ratios (HRs) with 95% confidence intervals (CIs). The study also included a subgroup analysis by cervical cancer stage. <i>Results</i>: The pooled analysis revealed that bevacizumab-based therapy significantly improved both PFS with HR 0.77 (95% CI: 0.58-0.96; <i>p</i> < 0.01; I<sup>2</sup> = 58%) and OS with HR 0.63 (95% CI: 0.45-0.89; <i>p</i> < 0.01; I<sup>2</sup> = 41%) in cervical cancer patients. Subgroup analysis by stage of cervical cancer demonstrated better efficacy of bevacizumab in metastatic stage IVB cervical cancer patients indicated by HR for PFS (0.69, 95% CI: 0.54-0.79; <i>p</i> < 0.01) and HR for OS (0.57, 95% CI: 0.46-0.73; <i>p</i> < 0.01). <i>Conclusions</i>: Bevacizumab exhibits a significant increase in PFS and OS, underscoring the efficacy of anti-angiogenesis therapy in cervical cancer, particularly in stage IVB metastatic cervical cancer patients.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
While veterinary pharmacy is common overseas, it has yet to gain traction in Japan. To clarify the actual situation in Japan, two surveys were conducted, targeting 4017 facilities (2000 pharmacies/drug stores, 2000 veterinary medical facilities, and 17 university-affiliated veterinary hospitals). We received 324 responses from pharmacy staff and 217 from veterinary hospital staff. Pharmacists were involved in drug therapy for companion animals either via direct discussion with veterinarians or by referrals for prescriptions from veterinarians (11 respondents). Veterinary staff and pharmacists showed a disparity regarding pharmacists' involvement in companion animal healthcare. Veterinary staff wanted pharmacists to provide pharmaceutical guidance, perform audits, supply drug information, and prepare drugs. Strong demand (72.2% of the veterinary staff) existed for consultations with pharmacists regarding medication issues. Veterinary medicine has evolved to meet the demand for the advanced care of companion animals. Veterinary staff have diverse and substantial requests for pharmacists. Integrating the expertise of both veterinary staff and pharmacists may facilitate a team-based approach to veterinary medicine and improve the quality of care for companion animals. Tailoring approaches to suit Japan's unique circumstances and creating a conducive environment for effective communication between pharmacists and veterinary staff are pivotal for advancing veterinary pharmacy in Japan.
{"title":"Current Situation for Pharmacists in Japanese Veterinary Medicine: Exploring the Pharmaceutical Needs and Challenges of Veterinary Staff to Facilitate Collaborative Veterinary Care.","authors":"Taisuke Konno, Hiroyuki Suzuki, Naoto Suzuki, Kouji Okada, Yosuke Nishikawa, Daisuke Kikuchi, Hitoshi Nakamura, Yuriko Murai","doi":"10.3390/pharmacy12060179","DOIUrl":"10.3390/pharmacy12060179","url":null,"abstract":"<p><p>While veterinary pharmacy is common overseas, it has yet to gain traction in Japan. To clarify the actual situation in Japan, two surveys were conducted, targeting 4017 facilities (2000 pharmacies/drug stores, 2000 veterinary medical facilities, and 17 university-affiliated veterinary hospitals). We received 324 responses from pharmacy staff and 217 from veterinary hospital staff. Pharmacists were involved in drug therapy for companion animals either via direct discussion with veterinarians or by referrals for prescriptions from veterinarians (11 respondents). Veterinary staff and pharmacists showed a disparity regarding pharmacists' involvement in companion animal healthcare. Veterinary staff wanted pharmacists to provide pharmaceutical guidance, perform audits, supply drug information, and prepare drugs. Strong demand (72.2% of the veterinary staff) existed for consultations with pharmacists regarding medication issues. Veterinary medicine has evolved to meet the demand for the advanced care of companion animals. Veterinary staff have diverse and substantial requests for pharmacists. Integrating the expertise of both veterinary staff and pharmacists may facilitate a team-based approach to veterinary medicine and improve the quality of care for companion animals. Tailoring approaches to suit Japan's unique circumstances and creating a conducive environment for effective communication between pharmacists and veterinary staff are pivotal for advancing veterinary pharmacy in Japan.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}